Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Low amyloid burden and favorable cognitive outcomes seen with DPP-4i use in Alzheimer disease-related cognitive impairment with diabetes
Please login or register first to view this content.
Login Register